#Global Trends – Page 16 – HEALTHCARE INSIGHTS

Key Development Global biopharmaceutical leader Bristol Myers Squibb (NYSE: BMY) has terminated its high-profile commercial manufacturing partnership with cell therapy... Read more

Tag: #Global Trends

FDA APPROVAL OF MIMRYLO ESTABLISHES HEPcidin MIMETICS AS A NEW THERAPEUTIC APPROACH IN POLYCYTHEMIA VERA

ORAL WEGOVY MOVES INTO CHINA: THE GLP-1 RACE IS SHIFTING FROM EFFICACY TO MARKET ACCESS

Infectious Disease & Oligonucleotide Milestone: Japan MHLW Grants World-First Approval for GSK’s Hibsago® (Bepirovirsen) as Pioneer Functional Cure for Chronic Hepatitis B

Upper GI Immuno-Oncology Milestone: US FDA Approves BeOne Medicines’ TEVIMBRA® (Tislelizumab) Regimen Combined with ZIIHERA® (Zanidatamab) and Chemotherapy in First-Line HER2-Positive GEA, Delivering 26.4 Months Median Overall Survival

Precision Oncology & Companion Diagnostics: US FDA Approves Roche’s PATHWAY HER2 (4B5) and VENTANA HER2 Dual ISH Assays as First Companion Diagnostics for HER2-Positive Esophageal and Metastatic Gastroesophageal Adenocarcinoma (GEA) to Direct ZIIHERA® Therapy

Biopharmaceutical Services & Oncology M&A: McKesson Expands Clinical Research and Commercialization Platform with $2.25 Billion Acquisition of Precision Medicine Group

Personalized Immuno-Oncology & mRNA Therapeutics: How the Merck/Moderna Neoantigen Vaccine (Intismeran Autogene) Functions, Pivotal Clinical Milestones, and Scalability Roadblocks in ‘N-of-1’ Biomanufacturing

Cell Therapy Manufacturing Bottlenecks: Bristol Myers Squibb Terminates $380 Million Commercial CAR-T Manufacturing Agreement with Cellares, Triggering 100 Workforce Layoffs

MedTech & Biosensing Innovation: US FDA Authorizes Abbott’s Libre Duo® 10 Day as World’s First Continuous Glucose and Ketone Monitoring (CGKM) Wearable for Diabetes Management

Facebook

Map

Online Members